Assessment
|
To Include
|
Frequency*
|
I
|
A
|
E
|
Current HIV-Specific Status and History
|
HIV |
| I | | |
Antiretroviral therapy |
Date of ART initiation Current ART regimen Previous ART regimens and reasons for any changes in regimens History of drug resistance, if known Adverse effects Current adherence status and challenges
| I | A | |
Viral load |
Most recent viral load Peak viral load
| I | A | |
CD4 cell count |
| I | A | |
AIDS-defining conditions |
Previous diagnoses and treatments History of malignancies and treatments Investigation of symptoms such as weight loss, night sweats, or chronic cough
| I | | |
Opportunistic infections |
Previous OI prophylaxis Previous diagnoses and treatment, including latent TB infection Adverse reactions to medications for OI prophylaxis or treatment
| I | | |
Current Medications
|
Complete medication list |
All medications: prescribed, over-the-counter, herbal preparations; include nonpharmacologic agents Potential drug-drug interactions Adverse effects Challenges with adherence to prescribed medications
| I | A | E |
Current General Medical Status and History
|
Immunizations |
| I | A | |
Age-related disease screening |
| I | A | |
Cardiovascular |
History of cardiac events, stroke, and treatment History of hypertension History of diabetes or insulin resistance Risk factors for CVD Family history of CVD
| I | A | |
Respiratory |
| I | A | |
Cancer |
History of prior malignancies and treatment Previous age-appropriate screening and results Family history of malignancies
| I | A | |
Renal |
| I | | |
Hepatic |
| I | | |
Endocrine |
Symptoms of thyroid dysfunction or hypogonadism Sexual dysfunction Weight loss or weight gain Family history of metabolic syndrome and thyroid disease History of osteoporosis and treatment, fractures, and previous screening History of lipodystrophy and treatment Use of hormonal therapy (including treatments obtained without prescription) Current and previous ART use, which may contribute to metabolic syndrome, lipodystrophy, and insulin resistance
| I | A | |
Gastrointestinal |
History of GI disease and treatment GI-related adverse effects of medications and effect (if any) on adherence to prescribed medications Family history of GI disease
| I | A | |
Vision |
Changes in vision, including blurry vision, double vision, flashes of light, loss of vision, use of glasses, and blindness or legal blindness
| I | A | |
Hearing |
| I | A | |
Neurologic |
History of neurocognitive assessment and results Assessment of current neurocognitive status, preferably using standardized tools such as the MoCA Test (requires an account), Mini-Cog, or MMSEHistory of neuropathy and treatment Assessment of symmetric distal polyneuropathy, which is common, particularly in patients exposed to earlier generations of ART
| I | A | |
Dermatologic |
History of psoriasis and treatment History of seborrheic dermatitis and treatment History of atopic dermatitis and xerosis and treatment History of skin cancer and treatment Note: Dermatitis can worsen with degree and duration of immunosuppression.
| I | A | |
Surgery |
| I | A | |
Pain |
| I | | E |
Sleep |
| I | | |
Nutrition |
| I | | E |
Frailty |
| I | A | |
Travel |
Recent travel; assess for potential exposure to infectious disease Frequency and location of international travel (work or leisure) Status of travel-related immunizations Lifetime travel history, if indicated
| I | A | |
Pets |
| I | A | |